Molecules, Vol. 24, Pages 3693: Metabolism, Transport and Drug –Drug Interactions of Silymarin
Molecules, Vol. 24, Pages 3693: Metabolism, Transport and Drug–Drug Interactions of Silymarin Molecules doi: 10.3390/molecules24203693 Authors: Xie Zhang Zhang Yuan Silymarin, the extract of milk thistle, and its major active flavonolignan silybin, are common products widely used in the phytotherapy of liver diseases. They also have promising effects in protecting the pancreas, kidney, myocardium, and the central nervous system. However, inconsistent results are noted in the different clinical studies due to the low bioavailability of silymarin. Extensive studies were conducted to explore the metabolism and transport of silymarin/silybin as well as the impact of its consumption on the pharmacokinetics of other clinical drugs. Here, we aimed to summarize and highlight the current knowledge of the metabolism and transport of silymarin. It was concluded that the major efflux transporters of silybin are multidrug resistance-associated protein (MRP2) and breast cancer resistance protein (BCRP) based on results from the transporter-overexpressing cell lines and MRP2-deficient (TR-) rats. Nevertheless, compounds that inhibit the efflux transporters MRP2 and BCRP can enhance the absorption and activity of silybin. Although silymarin does inhibit certain drug-metabolizing enzymes and drug transporters, such effects are unlikely to manifest in clinical settings. Overall, silymarin is a safe and well-tolerated phytomedicine.
Publication date: Available online 17 November 2019Source: European UrologyAuthor(s): Zhengzheng Xu, Guangzhe Ge, Bao Guan, Zhentao Lei, Xueyu Hao, Yuanyuan Zhou, Yue Shi, Huan Lu, Jilu Wang, Ding Peng, XiKang Wu, Huiying He, Bao Zhang, Xuesong Li, Liqun Zhou, Weimin Ci
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Pirus Ghadjar, Thomas Wiegel
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Elise De Bleser, Piet Ost
ConclusionsTattooing of axillary LNs is safe and easily performed. Tattooing was helpful in identifying the marked LN in the majority of cases. This technique helps to ensure that metastatic LNs are identified and removed at surgery after NAT.
Individuals who have multiple close relatives with pancreatic cancer should undergo surveillance for pancreatic cancer, according to updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.Reuters Health Information
Publication date: Available online 16 November 2019Source: Gynecologic Oncology ReportsAuthor(s): Hermineh Aramin, Pratistha Koirala, Abhishek Shah, Kendall Adams, Natalia Buza, Sapna Desai, Melissa Fairbairn, David Goldenberg, Wenli Gao, Linus Chuang, Ramapriya Vidhun, Vaagn Andikyan
Publication date: Available online 17 November 2019Source: Pharmacological ResearchAuthor(s): Ali Dehshahri, Milad Ashrafizadeh, Elham Ghasemipour Afshar, Abbas Pardakhty, Ali Mandegary, Reza Mohammadinejad, Gautam SethiAbstractTopoisomerase enzymes have shown unique roles in replication and transcription. These enzymes which were initially found in Escherichia coli have attracted considerable attention as target molecules for cancer therapy. Nowadays, there are several topoisomerase inhibitors in the market to treat or at least control the progression of cancer. However, significant toxicity, low solubility and poor pharm...
Publication date: Available online 16 November 2019Source: Journal of Evidence Based Dental PracticeAuthor(s): Walter J. Psoter, Erin T. Shope
ConclusionsOral HPV infection is significantly prevalent and widespread worldwide, particularly among men and among populations at risk. Prevalence has increased during the last two decades.
In conclusion, miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HMGB1. The miR-142-3p/HMGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients.Graphical abstractHigh-mobility group box 1 (HMGB1) is a direct functional target of miR-142-3p in breast cancer cells. MiR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of doxorubicin (DOX) by targeting HMGB1. The miR-142-3p/HMGB1 axis might be an important pathway regulating the sensitivity of breast cancer cells.